Fexuclue Adverse Reactions

A total of two clinical trials were conducted in patients with erosive esophagitis (EE). Of the subjects who participated in the clinical trials, 183 received 40 mg of the Product. Adverse events reported in clinical trials are as follow. Adverse events (1% or more) and adverse drug reactions (*) commonly reported in the Product administration group are shown in the following Table 2. (See Table 2.)

Click on icon to see table/diagram/image

Other adverse events reported in clinical trials with an incidence of less than 1% after administration of the Product are listed according to the major system organ class as follows.
Gastrointestinal disorders: Hiatal hernia, Brunner's gland hyperplasia.
Infections and infestations: Bronchitis, herpes simplex, influenza, periodontitis, pharyngitis, vaginal infections.
Skin and subcutaneous tissue disorders: Contact dermatitis, pruritus*, systemic pruritus', facial edema.
General disorders and administration site conditions: Chest discomfort, strange feeling', edema, pain, fever.
Nervous system disorders: Dizziness, dysgeusia.
Musculoskeletal and connective tissue disorders: Myalgia*, musculoskeletal pain, neck pain.
Eye disorders: Cataract, septum bleeding*, retinal laceration.
Ear and labyrinth disorders: Ear discomfort*.
Respiratory, thoracic and mediastinal disorders: Runny nose.
Metabolic and nutritional disorders: Hypertriglyceridemia.